Study Information
- PI: Toralf Reimer
- Study supported by EUBREAST
- Trial design: prospective randomised trial with focus to de-escalation of axillary surgery in the adjuvant setting
- Primary outcome: 5-year invasive disease-free survival (SLNB versus no SLNB in breast-conserving surgery)Key secondary outcome: 5-year invasive disease-free survival (SLNB alone versus completion ALND in pN1a(sn) cases)
Publications
Axillary Surgery in Breast Cancer — Primary Results of the INSEMA Trial – New England Journal of Medicine